Coming together with backgrounds in biochemistry, chemistry, hardware, molecular biology, photonics, semiconductor chips, and software, our leadership has one thing in common: solving problems no one has thought of yet and disrupting industries to make a global impact on human health.
Leadership
Jeff Hawkins
Chief Executive Officer
Jeff Hawkins
Chief Executive Officer
Mr. Hawkins brings over 20 years of experience at the world’s leading life science and diagnostics companies as an accomplished business leader and inventor. Prior to Quantum-Si, he was President and Chief Executive Officer of Truvian Sciences, Inc. where he led the evolution of the company’s benchtop blood testing system from a product concept through technology feasibility and into late-stage development. Prior to Truvian, Mr. Hawkins led the Reproductive and Genetic Health Business Unit at Illumina, Inc., where he oversaw the rapid global growth of next-generation sequencing into new and emerging markets. During his Illumina tenure, the business unit more than doubled in revenue and established clear market leadership across every major product line and geographic region. Before Illumina, Mr. Hawkins held roles of increasing responsibility across multiple functional areas for GenMark, Hologic, Third Wave Technologies and Abbott Laboratories. Mr. Hawkins holds a B.A. in Chemistry with honors from Concordia University and an MBA from Keller Graduate School of Management. He is co-inventor on 10 issued or pending patents spanning consumables, instrumentation, optics, manufacturing methods and designs.
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Patrick
Schneider, Ph.D.
President and Chief Operating Officer
Patrick Schneider, Ph.D.
President and Chief Operating Officer
Dr. Schneider has served in a number of roles at MilliporeSigma, including its predecessor entities (the life science business of Merck KGaA, Darmstadt, Germany), most recently as Senior Vice President, Strategy, Business Development and Innovation, and Chair of the Life Science Innovation Board from 2016 until April 2022, where he led strategy development, business development, and licensing for a global team of biologists, chemists and engineers. Prior to that, between 2006 to 2015, Dr. Schneider served as Vice President of the Bioscience Business Unit, Vice President of Research Content and Reagents Business, General Manager of New Business Initiatives R&D and Business Development, and Vice President of Research Reagents Business Unit. From 2003 to 2006, Dr. Schneider served as Vice President of Research & Development, Business Development & Scientific Affairs at Serologicals, Inc. Dr. Schneider received his Ph.D. in biology from University of California, Irvine.
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Grace Johnston, Ph.D.
Chief Commercial Officer
Grace Johnston, Ph.D.
Chief Commercial Officer
Grace Johnston has served as our Chief Commercial Officer since December 2022. She previously served as Chief Commercial Officer at Fortis Life Sciences from September 2020 until December 2022, where she was accountable for organic revenue contribution, annual growth targets, commercial go-to-market strategy, sales and marketing, as well as overall customer experience. Prior to that, Ms. Johnston served in various roles of increasing responsibility at Sartorius AG from March 2016 until September 2020, most recently as Senior Vice President of Lab Product & Services – Marketing and Strategy, and previously as Vice President of Marketing for Essen Bioscience (acquired by Sartorius). Prior to that, Ms. Johnston served in various roles of increasing responsibility at Merck KGaA-Millipore from 2009 to 2016, most recently as Head of Global Market Services & Strategy – Bioscience, and previously as Segment Market Manager and Product Manager Cell Analysis + Cell Culture Systems. Ms. Johnston received her Ph.D. in Molecular Neuroscience and B.A.s in Biology and Psychology from the University of Rochester, and participated in the Executive Leadership Program at Harvard Business School.
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Michael P.
McKenna
Executive Vice President, Product Development and Operations
Michael P.
McKenna, Ph.D.
Executive Vice President, Product Development and Operations
Michael P. McKenna, Ph.D. has served as Quantum-Si’s Executive Vice President, Product Development and Operations since May 2022, and as Quantum-Si’s President and Chief Operating Officer since December 2014 to May 2022.Prior to joining Quantum-Si, Dr. McKenna served as Vice President, R&D at Life Technologies Corporation, a global biotechnology company, from August 2011 to July 2014, and as a consultant to Life Technologies from February 2011 to August 2011. Prior to that, Dr. McKenna served as Chief Scientific Officer of Tethys Bioscience, Inc., a diagnostics company, from August 2004 to February 2011, and as Vice President of Curagen Corporation, a biopharmaceutical company, from 1993 to 2003. Dr. McKenna received his B.S. in molecular biology and German from Carnegie Mellon University and his Ph.D. in biology from Yale University.
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Todd
Rearick
Chief Technology Officer
Todd Rearick
Chief Technology Officer
Todd Rearick has served as Quantum-Si's Chief Technology Officer since January 2019. Prior to that Mr. Rearick served as Chief Technology Officer at Hyperfine Research from January 2018 to January 2019, and as Systems Engineer from June 2014 to January 2018. Prior to that Mr. Rearick was an Engineering Fellow at Life Technologies from October 2010 to June 2014, and Principal Engineer for Ion Torrent from May 2008 to October 2010. Prior to that Mr. Rearick was a Software Manager at Raindance Technologies from June 2006 to May 2008, and held several positions at Sycamore Networks, a telecommunications equipment manufacturer, from April 1999 to June 2006. Mr. Rearick started his career with the Naval Undersea Warfare Center (NUWC) in New London, Connecticut from 1995 to 1998. Mr. Rearick earned his B.S. in Engineering Science from Penn State University.
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Claudia Napal
Drayton
Chief Financial Officer
Claudia Napal
Drayton
Chief Financial Officer
Claudia Drayton has served as Quantum-Si’s Chief Financial Officer since April 2021. She previously served as Chief Financial Officer of CHF Solutions, Inc., or CHFS, from January 2015 to April 2021. During her tenure as CFO of CHFS, Ms. Drayton guided the company through the acquisition of its commercial product line, and the completion of several public equity offerings to finance the company’s commercial expansion. Prior to joining CHFS, Ms. Drayton spent 15 years at Medtronic plc, or Medtronic, a $30 billion global leader in the medical device industry. During her tenure at Medtronic, Ms. Drayton held multiple senior managerial finance positions, culminating with an assignment in Europe serving as Chief Financial Officer of the peripheral vascular business from 2010 to 2012 and, more recently, as Chief Financial Person of the integrated health solutions business from 2012 to 2014. In these capacities, her responsibilities and experiences included profitability management, strategic planning, mergers and acquisitions, planning and forecasting, and implementation of financial best practices. Before joining Medtronic, Ms. Drayton was an audit and business advisory manager at Arthur Andersen LLP for seven years. Ms. Drayton received her M.B.A. from the University of Minnesota’s Carlson School of Management and her B.S. from the University of Mary Hardin-Baylor and is a Certified Public Accountant (inactive)
[/et_pb_text][et_pb_text module_class="module-text" _builder_version="4.9.2" _module_preset="default"]Claudia Napal Drayton
Chief Financial Officer
Claudia Napal Drayton has served as Quantum-Si’s Chief Financial Officer since April 2021. She previously served as Chief Financial Officer of CHF Solutions, Inc., or CHFS, from January 2015 to April 2021. During her tenure as CFO of CHFS, Ms. Drayton guided the company through the acquisition of its commercial product line, and the completion of several public equity offerings to finance the company’s commercial expansion. Prior to joining CHFS, Ms. Drayton spent 15 years at Medtronic plc, or Medtronic, a $30 billion global leader in the medical device industry. During her tenure at Medtronic, Ms. Drayton held multiple senior managerial finance positions, culminating with an assignment in Europe serving as Chief Financial Officer of the peripheral vascular business from 2010 to 2012 and, more recently, as Chief Financial Person of the integrated health solutions business from 2012 to 2014. In these capacities, her responsibilities and experiences included profitability management, strategic planning, mergers and acquisitions, planning and forecasting, and implementation of financial best practices. Before joining Medtronic, Ms. Drayton was an audit and business advisory manager at Arthur Andersen LLP for seven years. Ms. Drayton received her M.B.A. from the University of Minnesota’s Carlson School of Management and her B.S. from the University of Mary Hardin-Baylor and is a Certified Public Accountant (inactive)
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Christian
LaPointe
General Counsel
Christian
LaPointe, Ph.D.
General Counsel
Christian LaPointe, Ph.D. has served as Quantum-Si’s General Counsel since November 2020. Prior to joining Quantum-Si, Dr. LaPointe served as General Counsel at ArcherDX, Inc., a genomics company, from January 2015 to August 2019, and as Deputy General Counsel at ArcherDX from August 2019 to October 2020. Dr. LaPointe also served as General Counsel to Celsee, Inc., a single cell analysis solutions provider, from August 2019 to June 2020. Previously, Dr. LaPointe was General Counsel at Thrive Bioscience, Inc., a cell culture instruments and software company, from August 2014 to July 2019, General Counsel of the Enzymatics enzyme solutions unit of QIAGEN N.V., from March 2013 to January 2015, General Counsel of Axios Biosciences, LLC, an oncology drug discovery company, from December 2012 to December 2014, and a litigation attorney at the law firm Sherin and Lodgen LLP from April 2012 to March 2013. Dr. LaPointe received his B.S. in biochemistry from the University of New Hampshire, his Ph.D. in biochemistry from Dartmouth College and his J.D. from Suffolk University Law School.
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]Results over rules:
Jonathan Rothberg
A prolific inventor and recipient of the Medal of Technology & Innovation under President Obama, Jonathan Rothberg pioneered high speed next-generation sequencing as well as semiconductor based sequencing. His next vision: Quantum-Si’s next-generation protein sequencing technology for truly accessible proteomics.
As the founder of several groundbreaking companies, Jonathan Rothberg has not only invented new industries, he has disrupted them as well.
Jonathan thrives on harnessing the power of semiconductor technology to create products for improving human health:
Ion Torrent
Ion Torrent disrupted the genomic sequencing industry—where slow and cost prohibitive technology was the norm—to make genomic sequencing more accessible to more brilliant minds.
Butterfly
Butterfly disrupted the ultrasound industry—where products are usually large, bulky, and hard to move around—bringing the portable ultrasound to the market and revolutionizing care in remote areas and regions.
Hyperfine
Hyperfine disrupted conventional MRIs—traditionally driving expensive and time consuming procedures—to put MRI imaging within reach of every patient regardless of location, in any healthcare facility in any country across the globe.
- White House National Medal of Technology and Innovation, awarded by President Obama
- Founder of Rothberg Institute for Childhood Diseases
- The first individual named a World Economic Forum’s Technology Pioneer four separate times
- Ernst and Young Entrepreneur of the Year
- The Wall Street Journal’s First Gold Medal for Innovation Recipient